 Single center trial included 10 patients in the age of 5-11 years with OI (confirmed mutations in COL1A1/A2) after at least 2 years of bisphosphonate treatment.  Denosumab treatment s.c. (Prolia®, Amgen Inc., Thousand Oaks, CA) 1mg per kg body weight four times in an interval of 12 weeks (+/-7days).  Measurement of aBMD at baseline and after 48 weeks  Frequent serum calcium and urinary desoxypiridinoline measurements for safety and efficacy analyses  Measurement of motor function at baseline, week 24, week 48  Denosumab increases vertebral areal bone mineral density and avoids new vertebral compression fractures in OI children.  Denosumab leads to severe and repetitive alterations of the calcium homeostasis.  Denosumab supresses bone resorption over 10-12 weeks.  Denosumab seems to be safe in a one-year treatment course if a sufficient calcium and vitamin D substitution is guaranteed.  Limitations: only short term data in 10 children are available yet; phase 3 trials are needed to assess risk benefit ratio detailed.
Osteogenesis imperfectaa pilot trial on treatment with the RANKL-antibody denosumab Osteogenesis imperfecta (OI) is a rare disease leading to bone fragility. Many genes are known to perturb formation and processing of collagen leading to a disturbed function of osteoblasts and osteoclasts. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been approved for osteoporosis treatment in adults. Almost no data about its use in children or in OI are available. We investigated efficacy and safety aspects after a 48 week treatment course in a phase-II-trial.
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